Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00733408. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with metastatic breast cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can prevent cancer growth by blocking the ability of cancer cells to grow and spread. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial evaluates a maintenance treatment with erlotinib and bevacizumab after Nab-paclitaxel and bevacizumab which may control cancer growth with biologic therapies.
Study identification
- NCT ID
- NCT00733408
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 59 participants
Conditions and interventions
Conditions
Interventions
- paclitaxel albumin-stabilized nanoparticle formulation Drug
- bevacizumab Biological
- erlotinib hydrochloride Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2008 (Actual)
- Primary completion
- Jul 5, 2017 (Actual)
- Completion
- Sep 28, 2017 (Actual)
- Last update posted
- Dec 4, 2018
2008 – 2017
United States locations
- U.S. sites
- 17
- U.S. states
- 6
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Anchorage Oncology Centre | Anchorage | Alaska | 99508 | — |
| Katmai Oncology Group | Anchorage | Alaska | 99508 | — |
| Providence Alaska Medical Center | Anchorage | Alaska | 99508 | — |
| Yuma Cancer Center | Yuma | Arizona | 85364 | — |
| Saint Joseph Regional Medical Center | Lewiston | Idaho | 83501 | — |
| Bozeman Deaconess Hospital | Bozeman | Montana | 59715 | — |
| Kalispell Regional Medical Center | Kalispell | Montana | 59901 | — |
| Bend Memorial Clinic | Bend | Oregon | 97701 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| Evergreen Hospital Medical Center | Kirkland | Washington | 98033 | — |
| Skagit Valley Hospital Regional Cancer Care Center | Mount Vernon | Washington | 98273 | — |
| Group Health Cooperative, Redmond | Redmond | Washington | 98052 | — |
| Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
| Olympic Medical Cancer Care Center | Sequim | Washington | 98384 | — |
| Spokane Valley Cancer Center-Mayfair | Spokane | Washington | 99208 | — |
| Multicare Medical Oncology Hematology | Tacoma | Washington | 98405 | — |
| Wenatchee Valley Medical Center | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00733408, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2018 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00733408 live on ClinicalTrials.gov.